Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?

Iovance Biotherapeutics reported strong Q2 earnings with revenue of $99.3 million (up 66% year-over-year), driven primarily by its FDA-approved cancer treatment Amtagvi. The company also significantly reduced losses to $47.3 million from $111.7 million in the prior year. With blockbuster potential for Amtagvi and a path toward profitability, analysts believe the stock could rise further despite current valuation concerns.